U.S. markets closed

Aditxt, Inc. (ADTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2900+0.0189 (+6.97%)
At close: 04:00PM EDT
0.2779 -0.01 (-4.17%)
After hours: 06:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.2711
Bid0.2779 x 1100
Ask0.2950 x 3000
Day's Range0.2600 - 0.2958
52 Week Range0.2410 - 3.9500
Avg. Volume603,112
Market Cap12.97M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.7200
Earnings DateNov 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ADTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aditxt, Inc.
    Daily – Vickers Top Insider Picks for 05/26/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Business Wire

    Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth

    RICHMOND, Va., April 14, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, today is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse Guthy-Renker, LLC ("Guthy-Renker"). This partnership will focus on building awareness and visibility among consumers and healthcare providers for the AditxtScore™ Immune Monitoring Platform. Aditxt plans to work

  • Business Wire

    Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th

    RICHMOND, Va., April 05, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX) has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the Company’s $14.5 million loan, plus interest to Cellvera Global Holdings LLC ("Cellvera"), formerly AiPharma Global Holdings LLC. The Company has signed the agreement as consideration for Aditxt’s separa

  • Business Wire

    Aditxt to Participate in the 2022 Virtual Growth Conference

    RICHMOND, Va., March 23, 2022--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced today that Company CEO & Co-Founder, Amro Albanna, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.